U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C10H17N
Molecular Weight 151.2487
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AMANTADINE

SMILES

NC12CC3CC(CC(C3)C1)C2

InChI

InChIKey=DKNWSYNQZKUICI-UHFFFAOYSA-N
InChI=1S/C10H17N/c11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7-9H,1-6,11H2

HIDE SMILES / InChI

Molecular Formula C10H17N
Molecular Weight 151.2487
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Amantadine hydrochloride has pharmacological actions as both an anti-Parkinson and an antiviral drug. The mechanism by which amantadine exerts its antiviral activity is not clearly understood. It appears to mainly prevent the release of infectious viral nucleic acid into the host cell by interfering with the function of the transmembrane domain of the viral M2 protein. In certain cases, amantadine is also known to prevent virus assembly during virus replication. It does not appear to interfere with the immunogenicity of inactivated influenza A virus vaccine. The mechanism of action of amantadine in the treatment of Parkinson's disease and drug-induced extrapyramidal reactions is not known. Data from earlier animal studies suggest that amantadine hydrochloride may have direct and indirect effects on dopamine neurons. More recent studies have demonstrated that amantadine is a weak, non-competitive NMDA receptor antagonist (K1 = 10µM). Although amantadine has not been shown to possess direct anticholinergic activity in animal studies, clinically, it exhibits anticholinergic-like side effects such as dry mouth, urinary retention, and constipation. Amantadine was approved by the FDA in 1966 as a prophylactic agent against Asian influenza, and eventually received approval for the treatment of influenza virus A in adults. In 1969, it was also discovered by accident to help reduce symptoms of Parkinson's disease, drug-induced extrapyramidal syndromes, and akathisia.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
10.0 µM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
MANTADINE HYDROCHLORIDE

Approved Use

Amantadine Hydrochloride Capsules, USP are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine Hydrochloride Capsules, USP are also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions.

Launch Date

5.40518384E11
Primary
MANTADINE HYDROCHLORIDE

Approved Use

Amantadine Hydrochloride Capsules, USP are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine Hydrochloride Capsules, USP are also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions.

Launch Date

5.40518384E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
636.2 ng/mL
100 mg 2 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AMANTADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
0.24 μg/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMANTADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
6413.6 ng × h/mL
100 mg 2 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AMANTADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
14.7 h
100 mg 2 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AMANTADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
33%
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMANTADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.8 g single, oral
Overdose
Dose: 0.8 g
Route: oral
Route: single
Dose: 0.8 g
Sources: Page: p.120
healthy, 2
n = 1
Health Status: healthy
Age Group: 2
Sex: M
Population Size: 1
Sources: Page: p.120
Disc. AE: Status epilepticus, Agitation...
AEs leading to
discontinuation/dose reduction:
Status epilepticus
Agitation
Diaphoresis
Vomiting
Sources: Page: p.120
3000 mg single, oral
Overdose
Dose: 3000 mg
Route: oral
Route: single
Dose: 3000 mg
Sources: Page: p.757
unhealthy, 23
n = 1
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 23
Sex: M
Population Size: 1
Sources: Page: p.757
Disc. AE: CNS toxicity...
AEs leading to
discontinuation/dose reduction:
CNS toxicity (grade 5)
Sources: Page: p.757
10 g single, oral
Overdose
Dose: 10 g
Route: oral
Route: single
Dose: 10 g
Co-administed with::
diphenhydramine, p.o(250 mg, single)
Sources: Page: p.174
unhealthy, 47
n = 1
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 47
Sex: F
Population Size: 1
Sources: Page: p.174
Disc. AE: Ventricular tachycardia...
AEs leading to
discontinuation/dose reduction:
Ventricular tachycardia
Sources: Page: p.174
274 mg 1 times / day multiple, oral
Recommended
Dose: 274 mg, 1 times / day
Route: oral
Route: multiple
Dose: 274 mg, 1 times / day
Sources: Page: p.605
unhealthy, 53.3
n = 27
Health Status: unhealthy
Condition: Multiple sclerosis
Age Group: 53.3
Sex: M+F
Population Size: 27
Sources: Page: p.605
Disc. AE: Serotonin syndrome, Dry mouth...
AEs leading to
discontinuation/dose reduction:
Serotonin syndrome (serious, 3.7%)
Dry mouth (3.7%)
Sources: Page: p.605
274 mg 1 times / day multiple, oral
Recommended
Dose: 274 mg, 1 times / day
Route: oral
Route: multiple
Dose: 274 mg, 1 times / day
Sources:
unhealthy, 63.9
n = 63
Health Status: unhealthy
Condition: Levodopa-Induced Dyskinesia in Parkinson Disease
Age Group: 63.9
Sex: M+F
Population Size: 63
Sources:
DLT: Visual hallucinations...
Disc. AE: Visual hallucinations, Peripheral edema...
Dose limiting toxicities:
Visual hallucinations (4.8%)
AEs leading to
discontinuation/dose reduction:
Visual hallucinations (7.9%)
Peripheral edema (4.8%)
Dry mouth (4.8%)
Sources:
420 mg 1 times / day multiple, oral
Highest studied dose
Dose: 420 mg, 1 times / day
Route: oral
Route: multiple
Dose: 420 mg, 1 times / day
Sources: Page: p.793
unhealthy, 66.4
n = 20
Health Status: unhealthy
Condition: Levodopa-Induced Dyskinesia in Parkinson Disease
Age Group: 66.4
Sex: M+F
Population Size: 20
Sources: Page: p.793
Disc. AE: Hallucinations, Balance disorder...
AEs leading to
discontinuation/dose reduction:
Hallucinations (15%)
Balance disorder (5%)
Confusional state (5%)
Dry mouth (5%)
Subdural hematoma (5%)
Constipation (5%)
Sources: Page: p.793
100 mg 3 times / day steady, oral
Dose: 100 mg, 3 times / day
Route: oral
Route: steady
Dose: 100 mg, 3 times / day
Sources:
unhealthy
n = 36
Health Status: unhealthy
Condition: Parkinson's disease
Population Size: 36
Sources:
Other AEs: Dry mouth...
Other AEs:
Dry mouth (below serious, 4 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Agitation Disc. AE
0.8 g single, oral
Overdose
Dose: 0.8 g
Route: oral
Route: single
Dose: 0.8 g
Sources: Page: p.120
healthy, 2
n = 1
Health Status: healthy
Age Group: 2
Sex: M
Population Size: 1
Sources: Page: p.120
Diaphoresis Disc. AE
0.8 g single, oral
Overdose
Dose: 0.8 g
Route: oral
Route: single
Dose: 0.8 g
Sources: Page: p.120
healthy, 2
n = 1
Health Status: healthy
Age Group: 2
Sex: M
Population Size: 1
Sources: Page: p.120
Status epilepticus Disc. AE
0.8 g single, oral
Overdose
Dose: 0.8 g
Route: oral
Route: single
Dose: 0.8 g
Sources: Page: p.120
healthy, 2
n = 1
Health Status: healthy
Age Group: 2
Sex: M
Population Size: 1
Sources: Page: p.120
Vomiting Disc. AE
0.8 g single, oral
Overdose
Dose: 0.8 g
Route: oral
Route: single
Dose: 0.8 g
Sources: Page: p.120
healthy, 2
n = 1
Health Status: healthy
Age Group: 2
Sex: M
Population Size: 1
Sources: Page: p.120
CNS toxicity grade 5
Disc. AE
3000 mg single, oral
Overdose
Dose: 3000 mg
Route: oral
Route: single
Dose: 3000 mg
Sources: Page: p.757
unhealthy, 23
n = 1
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 23
Sex: M
Population Size: 1
Sources: Page: p.757
Ventricular tachycardia Disc. AE
10 g single, oral
Overdose
Dose: 10 g
Route: oral
Route: single
Dose: 10 g
Co-administed with::
diphenhydramine, p.o(250 mg, single)
Sources: Page: p.174
unhealthy, 47
n = 1
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 47
Sex: F
Population Size: 1
Sources: Page: p.174
Dry mouth 3.7%
Disc. AE
274 mg 1 times / day multiple, oral
Recommended
Dose: 274 mg, 1 times / day
Route: oral
Route: multiple
Dose: 274 mg, 1 times / day
Sources: Page: p.605
unhealthy, 53.3
n = 27
Health Status: unhealthy
Condition: Multiple sclerosis
Age Group: 53.3
Sex: M+F
Population Size: 27
Sources: Page: p.605
Serotonin syndrome serious, 3.7%
Disc. AE
274 mg 1 times / day multiple, oral
Recommended
Dose: 274 mg, 1 times / day
Route: oral
Route: multiple
Dose: 274 mg, 1 times / day
Sources: Page: p.605
unhealthy, 53.3
n = 27
Health Status: unhealthy
Condition: Multiple sclerosis
Age Group: 53.3
Sex: M+F
Population Size: 27
Sources: Page: p.605
Visual hallucinations 4.8%
DLT
274 mg 1 times / day multiple, oral
Recommended
Dose: 274 mg, 1 times / day
Route: oral
Route: multiple
Dose: 274 mg, 1 times / day
Sources:
unhealthy, 63.9
n = 63
Health Status: unhealthy
Condition: Levodopa-Induced Dyskinesia in Parkinson Disease
Age Group: 63.9
Sex: M+F
Population Size: 63
Sources:
Dry mouth 4.8%
Disc. AE
274 mg 1 times / day multiple, oral
Recommended
Dose: 274 mg, 1 times / day
Route: oral
Route: multiple
Dose: 274 mg, 1 times / day
Sources:
unhealthy, 63.9
n = 63
Health Status: unhealthy
Condition: Levodopa-Induced Dyskinesia in Parkinson Disease
Age Group: 63.9
Sex: M+F
Population Size: 63
Sources:
Peripheral edema 4.8%
Disc. AE
274 mg 1 times / day multiple, oral
Recommended
Dose: 274 mg, 1 times / day
Route: oral
Route: multiple
Dose: 274 mg, 1 times / day
Sources:
unhealthy, 63.9
n = 63
Health Status: unhealthy
Condition: Levodopa-Induced Dyskinesia in Parkinson Disease
Age Group: 63.9
Sex: M+F
Population Size: 63
Sources:
Visual hallucinations 7.9%
Disc. AE
274 mg 1 times / day multiple, oral
Recommended
Dose: 274 mg, 1 times / day
Route: oral
Route: multiple
Dose: 274 mg, 1 times / day
Sources:
unhealthy, 63.9
n = 63
Health Status: unhealthy
Condition: Levodopa-Induced Dyskinesia in Parkinson Disease
Age Group: 63.9
Sex: M+F
Population Size: 63
Sources:
Hallucinations 15%
Disc. AE
420 mg 1 times / day multiple, oral
Highest studied dose
Dose: 420 mg, 1 times / day
Route: oral
Route: multiple
Dose: 420 mg, 1 times / day
Sources: Page: p.793
unhealthy, 66.4
n = 20
Health Status: unhealthy
Condition: Levodopa-Induced Dyskinesia in Parkinson Disease
Age Group: 66.4
Sex: M+F
Population Size: 20
Sources: Page: p.793
Balance disorder 5%
Disc. AE
420 mg 1 times / day multiple, oral
Highest studied dose
Dose: 420 mg, 1 times / day
Route: oral
Route: multiple
Dose: 420 mg, 1 times / day
Sources: Page: p.793
unhealthy, 66.4
n = 20
Health Status: unhealthy
Condition: Levodopa-Induced Dyskinesia in Parkinson Disease
Age Group: 66.4
Sex: M+F
Population Size: 20
Sources: Page: p.793
Confusional state 5%
Disc. AE
420 mg 1 times / day multiple, oral
Highest studied dose
Dose: 420 mg, 1 times / day
Route: oral
Route: multiple
Dose: 420 mg, 1 times / day
Sources: Page: p.793
unhealthy, 66.4
n = 20
Health Status: unhealthy
Condition: Levodopa-Induced Dyskinesia in Parkinson Disease
Age Group: 66.4
Sex: M+F
Population Size: 20
Sources: Page: p.793
Constipation 5%
Disc. AE
420 mg 1 times / day multiple, oral
Highest studied dose
Dose: 420 mg, 1 times / day
Route: oral
Route: multiple
Dose: 420 mg, 1 times / day
Sources: Page: p.793
unhealthy, 66.4
n = 20
Health Status: unhealthy
Condition: Levodopa-Induced Dyskinesia in Parkinson Disease
Age Group: 66.4
Sex: M+F
Population Size: 20
Sources: Page: p.793
Dry mouth 5%
Disc. AE
420 mg 1 times / day multiple, oral
Highest studied dose
Dose: 420 mg, 1 times / day
Route: oral
Route: multiple
Dose: 420 mg, 1 times / day
Sources: Page: p.793
unhealthy, 66.4
n = 20
Health Status: unhealthy
Condition: Levodopa-Induced Dyskinesia in Parkinson Disease
Age Group: 66.4
Sex: M+F
Population Size: 20
Sources: Page: p.793
Subdural hematoma 5%
Disc. AE
420 mg 1 times / day multiple, oral
Highest studied dose
Dose: 420 mg, 1 times / day
Route: oral
Route: multiple
Dose: 420 mg, 1 times / day
Sources: Page: p.793
unhealthy, 66.4
n = 20
Health Status: unhealthy
Condition: Levodopa-Induced Dyskinesia in Parkinson Disease
Age Group: 66.4
Sex: M+F
Population Size: 20
Sources: Page: p.793
Dry mouth below serious, 4 patients
100 mg 3 times / day steady, oral
Dose: 100 mg, 3 times / day
Route: oral
Route: steady
Dose: 100 mg, 3 times / day
Sources:
unhealthy
n = 36
Health Status: unhealthy
Condition: Parkinson's disease
Population Size: 36
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
yes [Ki 111.8 uM]
yes [Ki 1167 uM]
yes [Ki 236 uM]
yes [Ki 284 uM]
yes [Ki >1000 uM]
Drug as victim
PubMed

PubMed

TitleDatePubMed
Differential inhibitory effects of sulfated polysaccharides and polymers on the replication of various myxoviruses and retroviruses, depending on the composition of the target amino acid sequences of the viral envelope glycoproteins.
1991 Dec
Neurotoxicity of chlorpromazine and modulation by amantadine as a function of mouse strain.
1991 Fall
Neuroleptic malignant syndrome induced by haloperidol following traumatic brain injury.
1999 Dec
Amantadine-induced peripheral neuropathy.
1999 Nov 10
The role of glutamatergic transmission in the pathogenesis of levodopa-induced dyskinesias. Potential therapeutic approaches.
2001
A rapid assay for evaluation of antiviral activity against coxsackie virus B3, influenza virus A, and herpes simplex virus type 1.
2001 Jun
Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study.
2001 May
[Effect of the new potential anti-Parkinson agent, hymantane, on levels of monoamines and their metabolites in rat striatum (a microdialysis study)].
2001 Nov-Dec
An MCASE approach to the search of a cure for Parkinson's Disease.
2002 Apr 2
Chiral separation of enantiomeric 1,2-diamines using molecular imprinting method and selectivity enhancement by addition of achiral primary amines into eluents.
2002 Jan
Synthesis and antioxidant activity evaluation of novel antiparkinsonian agents, aminoadamantane derivatives of nitroxyl free radical.
2003 Aug 5
An artist's view of drug-induced hallucinosis.
2003 Jul
Long term motor complications of levodopa: clinical features, mechanisms, and management strategies.
2004 Aug
Prevention of influenza in the general population.
2004 Nov 9
Improved neurological function after Amantadine treatment in two patients with brain injury.
2005 Apr
Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD.
2005 Dec
High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.
2005 Feb 1
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
Glutamate receptors in neuroinflammatory demyelinating disease.
2006
[Cytosine demethylation in the tyrosine hydroxylase gene promoter in the hypothalamus cells of the rat brain under the action of an aminoadamantane derivative Ladasten].
2006 Jul
Amantadine-induced livedo reticularis: a report of two cases.
2006 Mar
Interferon signal transduction of biphenyl dimethyl dicarboxylate/amantadine and anti-HBV activity in HepG2 2.2.15.
2006 May
Simultaneous liquid chromatographic assay of amantadine and its four related compounds in phosphate-buffered saline using 4-fluoro-7-nitro-2,1,3-benzoxadiazole as a fluorescent derivatization reagent.
2006 May
Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
2006 Nov
Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line.
2006 Sep 15
Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model.
2007 Apr 16
Patents

Sample Use Guides

Uncomplicated Influenza A Virus Illness: Adult: 200 mg; two 100 mg capsules as a single daily dose. The daily dosage may be split into one capsule of 100 mg twice a day. In persons 65 years of age or older, the daily dosage is 100 mg. Parkinsonism: Adult: is 100 mg twice a day when used alone. Amantadine Hydrochloride Capsules have an onset of action usually within 48 hours. The initial dose is 100 mg daily for patients with serious associated medical illnesses or who are receiving high doses of other antiparkinson drugs. After one to several weeks at 100 mg once daily, the dose may be increased to 100 mg twice daily, if necessary.
Route of Administration: Oral
Amantadine markedly inhibited the proliferation of HepG2 and SMMC‑7721 cells in a dose‑ and time‑dependent manner and arrested the cell cycle at the G0/G1 phase
Substance Class Chemical
Created
by admin
on Fri Dec 16 16:36:54 UTC 2022
Edited
by admin
on Fri Dec 16 16:36:54 UTC 2022
Record UNII
BF4C9Z1J53
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AMANTADINE
HSDB   INN   MART.   MI   VANDF   WHO-DD  
INN  
Official Name English
GOCOVRI
Brand Name English
AMANTADINE [MI]
Common Name English
AMANTADINE [MART.]
Common Name English
AMANTADINE [VANDF]
Common Name English
ADAMANTAN-1-AMINE
Systematic Name English
amantadine [INN]
Common Name English
NSC-341865
Code English
AMANTIDINE
Common Name English
Amantadine [WHO-DD]
Common Name English
AMANTADINE [HSDB]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C93038
Created by admin on Fri Dec 16 16:36:54 UTC 2022 , Edited by admin on Fri Dec 16 16:36:54 UTC 2022
NCI_THESAURUS C281
Created by admin on Fri Dec 16 16:36:54 UTC 2022 , Edited by admin on Fri Dec 16 16:36:54 UTC 2022
NDF-RT N0000175542
Created by admin on Fri Dec 16 16:36:54 UTC 2022 , Edited by admin on Fri Dec 16 16:36:54 UTC 2022
NCI_THESAURUS C38149
Created by admin on Fri Dec 16 16:36:54 UTC 2022 , Edited by admin on Fri Dec 16 16:36:54 UTC 2022
WHO-ATC N04BB01
Created by admin on Fri Dec 16 16:36:54 UTC 2022 , Edited by admin on Fri Dec 16 16:36:54 UTC 2022
NDF-RT N0000175543
Created by admin on Fri Dec 16 16:36:54 UTC 2022 , Edited by admin on Fri Dec 16 16:36:54 UTC 2022
WHO-VATC QN04BB01
Created by admin on Fri Dec 16 16:36:54 UTC 2022 , Edited by admin on Fri Dec 16 16:36:54 UTC 2022
LIVERTOX NBK547954
Created by admin on Fri Dec 16 16:36:54 UTC 2022 , Edited by admin on Fri Dec 16 16:36:54 UTC 2022
Code System Code Type Description
FDA UNII
BF4C9Z1J53
Created by admin on Fri Dec 16 16:36:54 UTC 2022 , Edited by admin on Fri Dec 16 16:36:54 UTC 2022
PRIMARY
EPA CompTox
DTXSID8022117
Created by admin on Fri Dec 16 16:36:54 UTC 2022 , Edited by admin on Fri Dec 16 16:36:54 UTC 2022
PRIMARY
IUPHAR
4128
Created by admin on Fri Dec 16 16:36:54 UTC 2022 , Edited by admin on Fri Dec 16 16:36:54 UTC 2022
PRIMARY
NSC
341865
Created by admin on Fri Dec 16 16:36:54 UTC 2022 , Edited by admin on Fri Dec 16 16:36:54 UTC 2022
PRIMARY
RXCUI
620
Created by admin on Fri Dec 16 16:36:54 UTC 2022 , Edited by admin on Fri Dec 16 16:36:54 UTC 2022
PRIMARY RxNorm
DRUG CENTRAL
144
Created by admin on Fri Dec 16 16:36:54 UTC 2022 , Edited by admin on Fri Dec 16 16:36:54 UTC 2022
PRIMARY
EVMPD
SUB05389MIG
Created by admin on Fri Dec 16 16:36:54 UTC 2022 , Edited by admin on Fri Dec 16 16:36:54 UTC 2022
PRIMARY
MESH
D000547
Created by admin on Fri Dec 16 16:36:54 UTC 2022 , Edited by admin on Fri Dec 16 16:36:54 UTC 2022
PRIMARY
INN
1816
Created by admin on Fri Dec 16 16:36:54 UTC 2022 , Edited by admin on Fri Dec 16 16:36:54 UTC 2022
PRIMARY
CHEBI
2618
Created by admin on Fri Dec 16 16:36:54 UTC 2022 , Edited by admin on Fri Dec 16 16:36:54 UTC 2022
PRIMARY
CAS
768-94-5
Created by admin on Fri Dec 16 16:36:54 UTC 2022 , Edited by admin on Fri Dec 16 16:36:54 UTC 2022
PRIMARY
PUBCHEM
2130
Created by admin on Fri Dec 16 16:36:54 UTC 2022 , Edited by admin on Fri Dec 16 16:36:54 UTC 2022
PRIMARY
LACTMED
Amantadine
Created by admin on Fri Dec 16 16:36:54 UTC 2022 , Edited by admin on Fri Dec 16 16:36:54 UTC 2022
PRIMARY
DAILYMED
BF4C9Z1J53
Created by admin on Fri Dec 16 16:36:54 UTC 2022 , Edited by admin on Fri Dec 16 16:36:54 UTC 2022
PRIMARY
WIKIPEDIA
AMANTADINE
Created by admin on Fri Dec 16 16:36:54 UTC 2022 , Edited by admin on Fri Dec 16 16:36:54 UTC 2022
PRIMARY
ChEMBL
CHEMBL660
Created by admin on Fri Dec 16 16:36:54 UTC 2022 , Edited by admin on Fri Dec 16 16:36:54 UTC 2022
PRIMARY
HSDB
3202
Created by admin on Fri Dec 16 16:36:54 UTC 2022 , Edited by admin on Fri Dec 16 16:36:54 UTC 2022
PRIMARY
NCI_THESAURUS
C61632
Created by admin on Fri Dec 16 16:36:54 UTC 2022 , Edited by admin on Fri Dec 16 16:36:54 UTC 2022
PRIMARY
DRUG BANK
DB00915
Created by admin on Fri Dec 16 16:36:54 UTC 2022 , Edited by admin on Fri Dec 16 16:36:54 UTC 2022
PRIMARY
ECHA (EC/EINECS)
212-201-2
Created by admin on Fri Dec 16 16:36:54 UTC 2022 , Edited by admin on Fri Dec 16 16:36:54 UTC 2022
PRIMARY
MERCK INDEX
M1638
Created by admin on Fri Dec 16 16:36:54 UTC 2022 , Edited by admin on Fri Dec 16 16:36:54 UTC 2022
PRIMARY Merck Index
Related Record Type Details
TARGET ORGANISM->INHIBITOR
TRANSPORTER -> SUBSTRATE
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
SALT/SOLVATE -> PARENT
TRANSPORTER -> SUBSTRATE
EXCRETED UNCHANGED
Amantadine is primarily excreted unchanged in the urine, and in a study of six healthy volunteers, the ratio of amantadine renal clearance to apparent plasma clearance was 0.79 ± 0.17 (mean ± SD).
SALT/SOLVATE -> PARENT
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
METABOLIC ENZYME -> INHIBITOR
BINDER->LIGAND
BINDING
TRANSPORTER -> INHIBITOR
TARGET ORGANISM->INHIBITOR
Related Record Type Details
METABOLITE -> PARENT
URINE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Tmax PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC